Hims & Hers: Hers UK launches Care+; peptides under scrutiny
- Good news: Hers UK launched Care+ at £39 a month with a home metabolic blood test, taking the US model abroad.
- Bad news: STAT News and Medical Daily stress that compounded peptides have no FDA approval and no human randomised trials, as peptides go mainstream.
- Mixed: UK Care+ is optional, while US Care+ is mandatory, and take-up and blood test pricing are not disclosed.
Read the full notes
Hers UK has launched a Care+ monthly subscription plus a home metabolic blood test. It replicates the US Care+ model (validated with Testosterone and Peptides+) overseas and extends the drug fee, service fee and lab revenue layer internationally, consistent with Q3 international revenue up 321% to $233 million.
Read more
Meanwhile STAT News and Medical Daily frame the Hims and Noom peptide pushes as the moment peptides go mainstream, and point out there is no FDA approval and no human randomised controlled trials. The Peptides+ risk is a shift in regulatory tone, not demand.
Key evidence
- Hers UK official press release (PR Newswire UK), 19 Nov: a free Metabolic Deep Assessment questionnaire (about 10 minutes, 100+ factors) is the entry funnel, with two optional add-ons: a home Metabolic Health Test and the new Care+ monthly subscription at £39 a month, cancel anytime
- UK Care+ includes unlimited support calls, two 1-on-1 nutritionist sessions, a body-composition scale (muscle mass and weight), a metabolic blood test, and a 6-month 1-on-1 review with a UK-registered physician and women's health specialist
- International product VP quote: the aim is to be the UK's preferred integrated women's health platform, and this launch is bigger than any single specialty
- US Care+ is mandatory for Testosterone and Peptides+ ($49 a month, billed separately from the drug). The UK version is optional, not a prescription prerequisite
- UK Care+ adoption rates and the blood test unit price are not disclosed, so international Care+ penetration must be watched in future earnings
- Q3 international revenue up 321% ($233 million): overseas growth is not just the Eucalyptus consolidation, as the product layer is also expanding
Show 4 more
- STAT News and Medical Daily, 19 Nov: the Hims and Noom peptide pushes in the same week are called the peptide-mainstreaming moment. Both outlets stress that compounded peptides have no FDA approval and no human randomised controlled trials
- Peptides+ demand is not the risk: 10,000+ bookings in the first 15 days. The risk is regulatory tone tightening along with media coverage
- The HHS interim enforcement discretion of 28 Oct is the only legal basis for compounded Peptides+, a single point of failure for the regulatory anchor
- SEC EDGAR: three Form 4 filings on 18 Nov were closed out in yesterday's daily; no new company announcements
Catalysts to watch
- Future earnings disclosure of the international Care+ penetration rate
- A change in HHS enforcement posture on compounded peptides, such as any walk-back of the 28 Oct discretion
- Disclosure of UK Metabolic Health Test unit economics (adoption and pricing)
- A public FDA or FTC statement on Hims and Noom peptide marketing
- Further country launches of the Care+ model
Risks
- UK Care+ is optional while US Care+ is mandatory: the attach rate is uncertain, and drug-fee-only could prove to be the real international pattern
- Compounded peptide regulatory risk: the HHS interim enforcement discretion of 28 Oct is the only legal basis, and mainstream media scrutiny raises political pressure
- No international Care+ penetration metrics disclosed, so the thesis cannot be verified until the next earnings
- The longitudinal health data thesis is still unproven: the blood test opt-in rate is the key unknown
Sources 6
- PR Newswire UK, 19 Nov, Hers press release
- STAT News, 19 Nov
- Medical Daily, 19 Nov
- SEC EDGAR, 18 Nov Form 4 filings
- Hims Q3 earnings (international +321%, $233 million)
- HHS interim enforcement discretion, 28 Oct